Literature DB >> 22721643

Percutaneous transluminal renal denervation: a potential treatment option for polycystic kidney disease-related pain?

Sharad V Shetty, Timothy J Roberts, Markus P Schlaich.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22721643     DOI： 10.1016/j.ijcard.2012.05.114

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  4 in total

1.  Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Authors:  Arlene B Chapman; Olivier Devuyst; Kai-Uwe Eckardt; Ron T Gansevoort; Tess Harris; Shigeo Horie; Bertram L Kasiske; Dwight Odland; York Pei; Ronald D Perrone; Yves Pirson; Robert W Schrier; Roser Torra; Vicente E Torres; Terry Watnick; David C Wheeler
Journal:  Kidney Int       Date:  2015-03-18       Impact factor: 10.612

2.  Morphological evaluation of sympathetic renal innervation in patients with autosomal dominant polycystic kidney disease.

Authors:  Valentina Rovella; Manuel Scimeca; Elena Giannini; Adriana D'Ercole; Erica Giacobbi; Annalisa Noce; Gabriele D'Urso; Alessandro Anselmo; Pierluigi Bove; Giuseppe Santeusanio; Elena Bonanno; Maurizio Casasco; Silvestro Mauriello; Nicola Di Daniele; Alessandro Mauriello; Lucia Anemona
Journal:  J Nephrol       Date:  2019-04-25       Impact factor: 3.902

3.  Endovascular renal denervation: a novel sympatholytic with relevance to chronic kidney disease.

Authors:  Neil A Hoye; James C Baldi; Tracey L Putt; John B Schollum; Gerard T Wilkins; Robert J Walker
Journal:  Clin Kidney J       Date:  2013-11-08

4.  Effect of percutaneous renal denervation on blood pressure level and sympathetic activity in a patient with polycystic kidney disease.

Authors:  Aleksander Prejbisz; Jacek Kądziela; Jacek Lewandowski; Elżbieta Florczak; Ewa Zylińska; Mariusz Kłopotowski; Adam Witkowski; Andrzej Januszewicz
Journal:  Clin Res Cardiol       Date:  2013-12-10       Impact factor: 5.460
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.